DRugwatch BlogRSS 2.0

DRugwatch Blog > November 2011 > Is Contagion contagious enough to become a blockbuster?

Is Contagion contagious enough to become a blockbuster?

Natalia ReoutovaContributor: Natalia Reoutova

So after running around Aldgate East for a good half an hour in all possible directions trying to find this Turkish restaurant I was supposed to be having dinner at, having dinner (did I wash my hands?..), then running around a little bit more around Stepney Green and locating the cinema, I finally settled down to watch Contagion – in the nick of time and on the tiniest screen ever to be installed in a cinema.

Truth be told, I was curious about the film, but wasn’t expecting anything remotely above predictable. The sole reason I agreed to go is because of the star-studded cast: I seriously struggled to imagine that Matt Damon, Laurence Fishburne, Gwyneth Paltrow, Jude Law, and Kate Winslet would collectively decide to star in a typical disaster drama in the style of computer game-generated Resident Evil. Individually – maybe, although unlikely, but definitely not collectively. Although I guess it would have been quite fun to see Jude Law dressed up as a zombie and Matt Damon as a vampire (possibly -slayer; Catherine Hardwicke pay heed, I’m practically giving it away for when the Twilight saga is finally extinguished!).

Someone, of course, had to let out a cough when the lights went out – ha-ha. But what ensued after was so much above and beyond adolescent giggles and cynical smirks (mine was at the ready) that not only did I leave with a sense of thorough satisfaction, but also a profound respect for the makers of this film. For to do something so uncommercial, realistic, anti-hysterical, and generally scientifically accurate takes some guts. It almost felt like a mix between a documentary and an educational feature. I loved this film from beginning to the end. Just imagine what a mass epidemic of a virus with a very high mortality rate (aren’t you immensely grateful that it’s not outright lethal? I sure was) entails, what aspects of the very fabric of society it penetrates.

Guess the film takes on more of a political/socio-economic angle instead of giving a first-hand, personal account of the events– to elaborate on both in equal measures simply would have been impractical and part of me wishes that the personal had not been dwelled upon at all. But still, it was done in a demure, matter-of-fact way, which did nothing to detract from the political aspect. Don’t get me wrong – this is no political thriller and you’ll be left acutely disappointed if you’re after a healthy dose of conspiracy theories. The film is plain and simple (and did I mention, very real?) and this is what I liked about it so much.

Then there is, of course, the music. Slightly digital, slightly pulsating – perfectly evocative of the spread of the virus through the world and through the veins.

Frankly, in my opinion, the whole affair is more or less perfect – no cliff-hangers, no heart-breakers, no big evil pharma companies, no nonsense, but pure fact and science; well, and a little bit of profiteering, looting, kidnapping, and scape-goating thrown in for good measure.

However, I do wonder if the film is set to have any success with anyone without a science background. For once, I wasn’t smiling sardonically and patronising my gullible unsciencey friends. On the contrary, on this occasion, I’ve had to work very hard to kindle any sort of enthusiasm in them, so inconsolable they were at the lack of apocalyptic images and distorted human bodies mutating into undead things – the only mutation in this film was that of the virus and even that was pondered as “good or bad?”.

P. S. The only thing I’m not too pleased about in this film (hence my “more or less perfect” comment) is that they showed a 3D-simulated protein-protein complex in ChemSketch and passed it off as a virus-host aggregate, with the virus in this case being infinitely larger than the host cell. But then again, I might have misunderstood and they could have been referring to the viral antigen binding to the receptor on the surface of the host cell, which would have made a lot more sense.

P. P. S. Don’t forget to wash your hands before every meal!

Posted on: 11/7/2011 1:55:12 PM | with 1 comments

Tags: Just for Fun, Natalia Reoutova

Trackback URL: http://decisionresources.com/trackback/0cffe344-837b-4378-9f52-29f4b1861f6b/Is-Contagion-contagious-enough-to-become-a-blockbuster-.aspx?culture=en-us

Tom Oliver
Very interesting! Always nice to see a movie with a scientific theme and some realism. Will try and go to see it.
11/7/2011 11:29:35 AM

Leave comment Subscribe

What is the abbreviation for Accountable Care Organization?


rss twitter linkedin


DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Next Steps for Vorapaxar: EU PAD Label and Antidote Development?
Post date:
2/17/2015 10:49:37 AM
Post Summary:

Stefanie Matlok Graeme GreeneWriiten by: Stefanie Hoffart and Graeme Green

Topic: Cardiovascular

On January 19, 2015, the European Medicines Agency (EMA) approved the thrombin receptor antagonist vorapaxar (Merck’s Zontivity) for secondary prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI), co-administered with acetylsalicylic acid (ASA) and, if necessary, clopidogrel.

Post title:
Bococizumab: Late to Great? Dyslipidemia Déjà vu?
Post date:
2/12/2015 3:58:28 PM
Post Summary:
Tim BlackstockContributor: Tim Blackstock
Topics: Cardiovascular

The link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well established, as is, the evidence showing that agents that reduce LDL-C can prevent CV events.

Post title:
Sandoz’s Biosimilar Filgrastim Scores Positive Recommendation from FDA Advisory Committee
Post date:
1/22/2015 3:44:26 PM
Post Summary:
Contributors: Anees Malik and Hristina Ivanova

The unanimous recommendation by the Oncologic Drugs Advisory Committee (ODAC) for FDA approval of Sandoz’s biosimilar filgrastim (EP2006; Zarxio)–the first biosimilar filing to be accepted in the United States– moves the biosimilar product tantalizingly close to FDA approval. Oncology, Biosimilars, “Anees Malik”, “Hristina Ivanova”

Post title:
AstraZeneca’s Brilinta Meets Primary End Point in PEGASUS-TIM 54 Study
Post date:
1/15/2015 4:53:03 PM
Post Summary:
Conor WalshContributor: Conor Walsh

AstraZeneca yesterday (January 14, 2015) announced that the Phase III PEGASUS-TIMI 54 study—a large-scale outcomes trial involving over 21,000 post-myocardial infarction (MI) patients—successfully met its primary efficacy end point. The company also reported that preliminary analysis did not reveal any unexpected safety issues. This study represents the first of several large studies that are set to complete over the next two years seeking to expand Brilinta’s (ticagrelor) label and drive sales growth.

Post title:
Cancer Drugs Funding in England is Flawed and Needs Reform
Post date:
1/14/2015 4:47:28 PM
Post Summary:

Contributor: Dan Roberts PhD

In 2011, the UK government introduced the Cancer Drugs Fund (CDF) in England, which funds cancer drugs which have not been deemed cost-effective or have not yet been assessed by the National Institute of Health and Care Excellence (NICE).

Decision Resources Group brands include: